Immunohistochemistry analysis of p53 and ki-67 proteins in oral lichen planus and normal oral mucosa

Iranian Journal of Public Health

Volumn 38, Issue 2, 2009, Pages 37-43

  Agha Hosseini, F ^a   Khalili, M ^a   Rohani, B ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Immunohistochemistry; Ki 67; Oral lichen planus; P53

Indexed keywords

EID: 68649101556     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Conrotto D, Carbone M, Carrozzo M, Arduino P, Broccoletti R, Pentenero M, Gandolfo S (2006). Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial. British Journal Dermatology, 154: 139-45.
2. Jang-jear L, Mark-Yenping K, Shhi-Jung C, Chun-Pin C, Jiiangg-Huei J, et al. (2005). Higher expression of p53 and proliferative cell nuclear antigen (PCNA) in atrophic oral lichen planus and patients with areca quid chewing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 99: 471-78.
3. Carrozzo M, Uboldi de Capo M, Dametto E (2004). Tumor necrosis factor-and interferon-polymorphisms contribute to susceptibility to oral lichen-planus. J Invest Dermatol, 122: 87-94.
4. th ed. BC Decker Inc, Hamilton, Ontario.
5. Ebrahimi M, Wahlin YB, Coates PJ, Wiik A, Roos G, Nylander K (2007). Detection of antibodies against p63 and p73 isoforms in sera from patients diagnosed with oral lichen planus. J Oral Pathol Med, 36(2): 93-8.
6. Montebugnoli L, Farnedi A, Marchetti C, Magrini E, Pession A, Foschini MP (2006). High proliferative activity and chromosomal instability in oral lichen planus. Int J Oral Maxillofac Surg, 35(12): 1140-44.
7. Acay RR, Felizzola CR, Araujo NS, Sousa SOM (2006). Evaluation of proliferative potential in oral lichen planus and oral lichenoid lesions using immunohistochemical expression of p53 and Ki67. Oral Oncol, 42(5): 475-87.
8. Tizeira L, Aguas SC, Sano SM (2003). Malignant transformation of atypical oral lichen planus: a review of 32 cases. J Med Oral, 8 (1): 2-9.
9. Epstein JB, Wan LS, Gorsky M, Zhang L (2003). Oral lichen planus: progress in understanding its malignant potential and the implications for clinical management. J Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 96 (1): 32-7.
10. Mignogna MD, Fedele S, Lo Russo L (2006). Dysplasia/neoplasia surveillance in oral lichen planus patients: A description of clinical criteria adopted at a single centre and their impact on prognosis. J Oral Oncol, Feb1; Abstract [Epub ahead of print].
11. Bascones-Ilundain C, Gonzales-Moles MA, Esparza-Gomez G, Gil-Montoya JA, Bascones-Martinez A (2006). Importance of apoptotic mechanisms in inflammatory infiltrate of oral lichen planus lesions. J Anticancer Res, 26(1A): 357-62.
12. Ebrahimi M, Boldrup L, Coates PJ, Wahlin YB, Bourdon JC, Nylander K (2007). Expression of novel p53 isoforms in oral lichen planus. J Oral Oncol, Apr 4; [Epub ahead of print].
13. nd ed. WB Saunders Company, Philadelphia.
14. th ed. Saunders Company.
15. Hirota M, Ito T, Okudela K, Kawabe R, Yazawa T, Hayashi H, Nakatani Y, Fujita K, Kitamura H (2002). Cell proliferation activity and the expression of cell cycle regulatory proteins in oral lichen planus. J Oral Pathol Med, 31: 204-12.
16. 53 Mutation Database Analysis & Search. Genes & Development, 10: 1045-72.
17. Hornick JL, Fletcher CDM (2002). Immuno-histochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol, 117: 188-93.
18. Scully C, Eisen D, Carrozzo M (2000). The management of oral lichen planus. Am J Clin Dermatol, 1: 287-306.
19. van der Meij EH, Schepman KP, van der Waal I (2003). The possible premalignant character of lichen planus and oral lichenoid lesions: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 96(2): 164-71.
20. Tanda N, Mori S, Saito K, Ikawa K, Sakamoto S (2000). Expression of apoptotic signaling proteins in leukoplakia and oral lichen planus: quantitative and topographical studies. J Oral Pathol Med, 29: 385-93.
21. 53 mutations. A study of oral mucosa in Iceland. European Journal of Oral Sciences, 110(3): 192.
22. van der Meij EH, Schepman KP, Smeele LE (1999). A review of the recent literature regarding malignant transformation of oral lichen planus. J Oral Surg Oral Med Oral pathol, 88 (3): 307-10.
23. Hietanen J, Paasonen MR, Kuhlefelt M, Malmstrom M (1999). A retrospective study of oral lichen planus patients with concurrent or subsequent development of malignancy. J Oral Oncol, 35(3): 278-82.
24. th ed. Saunders Company, Philadelphia.
25. 53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. J Oral Pathol Med, 21: 404-408.
26. 53 gene expression and mutational analysis, combined with growth fraction assessment, in oral lichen planus. J Oral Pathol Med, 27: 318-24.
27. Gonzalez-Moles MA, Gil-Montoya JA, Ruiz-Avila I, Esteban F, Bascones-Martines A (2007). Differences in the expression of p53 protein in oral lichen planus based on the use of monoclonal antibodies Do7 and pAb 240. Oral Oncology, September.
28. 53 expression in biopsies of oral lichen planus undergoing malignant evolution. J Oral Pathol Med, 30: 135-40.
29. 53, bcl-2, and ki-67 Immunoreactivity and of Apoptosis in Normal Oral Epithelium and in Premalignant and Malignant Lesions of the Oral Cavity. J Oral Maxillofac Surg, 60: 532-40.